%0 Journal Article
%T Perfil dos usu¨¢rios de anticitocinas disponibilizadas pelo Sistema ¨²nico de Sa¨²de no estado do Paran¨¢ para o tratamento da artrite reumatoide
%A Wiens
%A Astrid
%A Grochocki
%A M£¿nica Cavichiolo
%A Pontarolli
%A Deise Regina Sprada
%A Venson
%A Rafael
%A Correr
%A Cassyano Janu¨¢rio
%A Pontarolo
%A Roberto
%J Revista Brasileira de Reumatologia
%D 2012
%I Sociedade Brasileira de Reumatologia
%R 10.1590/S0482-50042012000200005
%X introduction: the brazilian unified health care system (sus) offers treatment for patients with ra through federal funding (ministry of health) and state co-financing. the clinical protocol and therapeutic guidelines for the treatment of rheumatoid arthritis describe the therapeutic regimen for the disease, including the anticytokines adalimumab, etanercept or infliximab. objectives: the aim of this study was to evaluate the profile of registered users of those anticytokines, biologics registered in the information system of the pharmaceutical assistance specialized division, managed by the paran¨¢ state drug center. methods: a cross-sectional study regarding data from march 2010 was conducted. based on dispensation data, information regarding the following variables were collected: age; gender; regional health care centers; international classification of diseases (icd); and drug dispensed. in addition, the monthly cost with anticytokines for the sus was calculated. results: in the state of paran¨¢, 923 patients on anticytokines were identified, 40%, 44% and 16% of whom receiving adalimumab, etanercept and infliximab, respectively. this generated a monthly cost of r$3,403,195.59. regarding the icd, the distribution of patients was as follows: 55% had icd m05.8; 27%, icd m06.0; 9%, icd m6.8; 8%, icd m5.0; and 1% had other icds related to the disease. the regional health care centers of the state of paran¨¢ with the largest number of patients on anticytokines were in the following municipalities: ponta grossa; corn¨¦lio proc¨®pio; londrina; cianorte; maring¨¢; irati; and campo mour£¿o. conclusion: this study assessed the distribution and profile of users of anticytokines for the rheumatoid arthritis treatment covered by the sus in the state of paran¨¢, in march 2010.
%K rheumatoid arthritis
%K therapeutics
%K antirheumatic agents.
%U http://www.scielo.br/scielo.php?script=sci_abstract&pid=S0482-50042012000200005&lng=en&nrm=iso&tlng=en